Peptide-Based Vaccines: An Efficient Alternative to Combat Infectious Diseases and Drug Resistance

Dear Colleagues,

As the world is already struggling with the rapid emergence of drug resistance and scarcity of efficient antibiotics, the outbreak of new infectious agents such as SARS-CoV-2 has made the development of new antimicrobial agent or strategies to fight against these challenges urgent. Peptide-based vaccines are recognized as one such potential strategy for combatting drug resistance and new infections. Vaccines have already been proven to improve the management of infectious diseases as they aim to prevent infectious disease rather than treat it. Further, the use of antimicrobial peptides (AMPs) as subunit vaccines or adjuvants is another potential strategy with which to combat infections and thus slow down the evolution of drug resistance.

For this Special Issue, authors are invited to submit original research, review articles, short communications, case series, and opinion papers related to but not limited to the following specific topics of interest:

1. Characterization and design of novel-peptide-based vaccines or therapies.
2. Strategies for the development of peptide-based vaccines against infectious diseases.
3. Peptide-based vaccines and immunotherapies to combat cancer.
4. Applications and strategies to use peptide-based vaccines against autoimmune disease.
5. Peptide-based vaccines to combat against fungal infections and antifungal drug resistance.
6. Protein engineering strategies to design and alter the pattern of immunodominance in peptide-based vaccines.
7. Combination treatment strategies of peptide-based vaccines with other drugs or therapies to improve efficacy.

Peptide-based immunotherapies in clinical trials and therapeutics.

Dr. Piyush Baindara
Dr. Ravinder Kumar
Dr. Santi Mohan Mandal
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• peptide-based vaccines
• drug resistance
• protein engineering
• infectious diseases
• antibacterial
• antifungal
• antiviral
• immunotherapies
• therapeutics